HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
25 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
ERCC5
ERCC excision repair 5, endonuclease
Chromosome 13 Β· 13q33.1
NCBI Gene: 2073Ensembl: ENSG00000134899.25HGNC: HGNC:3437UniProt: P28715
305PubMed Papers
22Diseases
0Drugs
73Pathogenic Variants
FUNCTIONAL ROLE
DNA RepairHomologous RecombinationHub Gene
RESEARCH IMPACT
Variant-Rich
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
DNA replication factor A complexbubble DNA bindingRNA polymerase II complex bindingresponse to UVxeroderma pigmentosum group GXeroderma pigmentosum complementation group GCOFS syndromexeroderma pigmentosum-Cockayne syndrome complex
✦AI Summary

ERCC5 encodes a structure-specific endonuclease that plays critical roles in multiple DNA repair pathways. The protein functions primarily in nucleotide excision repair (NER) by making 3' incisions at DNA damage sites and binding repair bubble substrates 1. ERCC5 also participates in transcription-coupled NER, cooperating with ERCC6/CSB to recognize stalled RNA polymerase II and stimulate repair bubble formation 2. Additionally, the enzyme contributes to base excision repair by enhancing DNA glycosylase NTHL1 activity 3 and homologous recombination repair by recruiting RAD51, BRCA2, and PALB2 to damaged DNA sites 4. ERCC5 is essential for maintaining replication fork stability and genomic integrity 1. Mutations in ERCC5 cause xeroderma pigmentosum complementation group G and cerebro-oculo-facio-skeletal syndrome, characterized by DNA repair deficiency and accelerated aging 5. Polymorphisms in ERCC5 are associated with increased cancer risk, particularly for gastric, breast, cervical, esophageal, and laryngeal cancers 6789. In cancer therapy, ERCC5 expression levels may predict treatment response, with increased ERCC5 associated with enhanced efficacy of certain DNA-damaging agents 10.

Sources cited
1
ERCC5 makes 3' incisions in NER and binds DNA repair bubble substrates
PMID: 32522879
2
ERCC5 cooperates with ERCC6/CSB in transcription-coupled NER
PMID: 16246722
3
ERCC5 enhances DNA glycosylase NTHL1 activity in base excision repair
PMID: 9927729
4
ERCC5 recruits RAD51, BRCA2, and PALB2 in homologous recombination repair
PMID: 26833090
5
ERCC5 mutations cause accelerated aging and DNA repair deficiency
PMID: 27556946
6
ERCC5 polymorphisms associated with gastric cancer risk
PMID: 27323183
7
ERCC5 polymorphisms associated with breast cancer risk
PMID: 26045839
8
ERCC5 polymorphisms associated with cervical cancer risk
PMID: 36195778
9
ERCC5 polymorphisms associated with multiple cancer risks
PMID: 36033436
10
ERCC5 expression levels predict cancer treatment response
PMID: 37491889
Disease Associationsβ“˜22
xeroderma pigmentosum group GOpen Targets
0.78Strong
Xeroderma pigmentosum complementation group GOpen Targets
0.75Strong
COFS syndromeOpen Targets
0.72Strong
xeroderma pigmentosum-Cockayne syndrome complexOpen Targets
0.69Moderate
xeroderma pigmentosumOpen Targets
0.68Moderate
genetic disorderOpen Targets
0.41Moderate
cholelithiasisOpen Targets
0.40Moderate
ovarian cancerOpen Targets
0.40Weak
melanomaOpen Targets
0.38Weak
cutaneous melanomaOpen Targets
0.37Weak
carcinoma of liver and intrahepatic biliary tractOpen Targets
0.37Weak
colorectal adenocarcinomaOpen Targets
0.37Weak
hemangioblastomaOpen Targets
0.37Weak
Hepatobiliary NeoplasmOpen Targets
0.37Weak
Ileal Neuroendocrine Tumor G1Open Targets
0.37Weak
lymphoid neoplasmOpen Targets
0.37Weak
Ovarian Endometrioid Adenocarcinoma with Squamous DifferentiationOpen Targets
0.37Weak
pancreatic neoplasmOpen Targets
0.37Weak
prostate carcinomaOpen Targets
0.37Weak
skin squamous cell carcinomaOpen Targets
0.37Weak
Cerebro-oculo-facio-skeletal syndrome 3UniProt
Xeroderma pigmentosum complementation group GUniProt
Pathogenic Variants73
NM_000123.4(ERCC5):c.2878G>T (p.Glu960Ter)Pathogenic
Xeroderma pigmentosum, group G|Xeroderma pigmentosum|not provided
β˜…β˜…β˜†β˜†2026β†’ Residue 960
NM_000123.4(ERCC5):c.2413G>A (p.Gly805Arg)Pathogenic
not provided|Xeroderma pigmentosum
β˜…β˜…β˜†β˜†2026β†’ Residue 805
NM_000123.4(ERCC5):c.205C>T (p.Arg69Ter)Pathogenic
Xeroderma pigmentosum, group G|not provided|Xeroderma pigmentosum
β˜…β˜…β˜†β˜†2025β†’ Residue 69
NM_000123.4(ERCC5):c.1753G>T (p.Glu585Ter)Pathogenic
not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 585
NM_000123.4(ERCC5):c.2705dup (p.Asn902fs)Pathogenic
See cases|Cerebrooculofacioskeletal syndrome 3
β˜…β˜…β˜†β˜†2025β†’ Residue 902
NM_000123.4(ERCC5):c.2375C>T (p.Ala792Val)Likely pathogenic
Xeroderma pigmentosum, group G|Xeroderma pigmentosum, group G;Cerebrooculofacioskeletal syndrome 3|Xeroderma pigmentosum
β˜…β˜…β˜†β˜†2025β†’ Residue 792
NM_000123.4(ERCC5):c.2836G>T (p.Gly946Ter)Pathogenic
Cerebrooculofacioskeletal syndrome 3;Xeroderma pigmentosum, group G|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 946
NM_000123.4(ERCC5):c.1115_1118del (p.Arg372fs)Pathogenic
Xeroderma pigmentosum, group G|not provided|Xeroderma pigmentosum, group G;Cerebrooculofacioskeletal syndrome 3
β˜…β˜…β˜†β˜†2024β†’ Residue 372
NM_000123.4(ERCC5):c.1173dup (p.Lys392Ter)Pathogenic
Xeroderma pigmentosum|Xeroderma pigmentosum, group G;Cerebrooculofacioskeletal syndrome 3
β˜…β˜…β˜†β˜†2024β†’ Residue 392
NM_000123.4(ERCC5):c.2751del (p.Lys917fs)Pathogenic
Xeroderma pigmentosum, group G|Xeroderma pigmentosum|not provided|Xeroderma pigmentosum, group G;Cerebrooculofacioskeletal syndrome 3
β˜…β˜…β˜†β˜†2024β†’ Residue 917
NM_000123.4(ERCC5):c.2453C>T (p.Ala818Val)Pathogenic
Xeroderma pigmentosum|not provided
β˜…β˜…β˜†β˜†2023β†’ Residue 818
NM_000123.4(ERCC5):c.2606_2607del (p.Val869fs)Pathogenic
Xeroderma pigmentosum|not provided
β˜…β˜…β˜†β˜†2022β†’ Residue 869
NM_000123.4(ERCC5):c.673-2A>GPathogenic
not provided|Cerebrooculofacioskeletal syndrome 3;Xeroderma pigmentosum, group G
β˜…β˜…β˜†β˜†2021
NM_000123.4(ERCC5):c.996_997del (p.Lys333fs)Pathogenic
not provided
β˜…β˜†β˜†β˜†2026β†’ Residue 333
NM_000123.4(ERCC5):c.2784dup (p.Asn929Ter)Pathogenic
not provided
β˜…β˜†β˜†β˜†2026β†’ Residue 929
NM_000123.4(ERCC5):c.2200-2A>TLikely pathogenic
not provided
β˜…β˜†β˜†β˜†2026
NM_000123.4(ERCC5):c.2518_2521del (p.Phe840fs)Pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 840
NM_000123.4(ERCC5):c.2713del (p.Lys904_Ile905insTer)Pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 904
NM_000123.4(ERCC5):c.2698C>T (p.Gln900Ter)Pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 900
NM_000123.4(ERCC5):c.2739del (p.Lys913_Val914insTer)Pathogenic
Cerebrooculofacioskeletal syndrome 3
β˜…β˜†β˜†β˜†2025β†’ Residue 913
View on ClinVar β†—
Related Genes
XPAProtein interaction100%RAD23BProtein interaction100%ATMProtein interaction100%CETN2Protein interaction100%ERCC1Protein interaction100%ERCC2Protein interaction100%
Tissue Expression6 tissues
Liver
100%
Lung
73%
Ovary
73%
Brain
34%
Bone Marrow
17%
Heart
9%
Gene Interaction Network
Click a node to explore
ERCC5XPARAD23BATMCETN2ERCC1ERCC2
PROTEIN STRUCTURE
Preparing viewer…
PDB5EKF Β· 2.00 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.77LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.63 [0.51–0.77]
RankingsWhere ERCC5 stands among ~20K protein-coding genes
  • #1,133of 20,598
    Most Researched305 Β· top 10%
  • #1,004of 5,498
    Most Pathogenic Variants73 Β· top quartile
  • #6,175of 17,882
    Most Constrained (LOEUF)0.77
Genes detectedERCC5
Sources retrieved25 papers
Response timeβ€”
πŸ“„ Sources
25β–Ό
1
Efficacy of Exome-Targeted Capture Sequencing to Detect Mutations in Known Cerebellar Ataxia Genes.
PMID: 29482223
JAMA Neurol Β· 2018
1.00
2
Polymorphisms in ERCC4 and ERCC5 and risk of cancers: Systematic research synopsis, meta-analysis, and epidemiological evidence.
PMID: 36033436
Front Oncol Β· 2022
0.90
3
Association between ERCC5 gene polymorphisms and breast cancer risk.
PMID: 26045839
Int J Clin Exp Pathol Β· 2015
0.80
4
ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma.
PMID: 21287534
Cancer Β· 2011
0.76
5
Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings.
PMID: 30306255
J Cancer Res Clin Oncol Β· 2018
0.70